Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (Nasdaq: ARTL) will present expanded clinical data on ART26.12 and interim Phase 2 data on ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit on October 15–16, 2025 in Boston.

Key findings: ART26.12 single ascending dose study showed safety at single doses up to 1050 mg, predictable linear plasma exposure, and potential dosing flexibility in fed or fasted states. ART27.13 Phase 2 interim data in cancer anorexia showed treated patients (up to 1300 µg/day on average) gained >b>6% body weight versus placebo patients who lost an additional 5%, with a similar tolerability profile to earlier stages to date.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $2.0 million in gross proceeds. The offering consisted of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.

The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares to cover over-allotments. R.F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's existing shelf registration statement.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $2.0 million public offering. The offering consists of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.

The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares. The offering, managed by R.F. Lafferty & Co. as the sole book-runner, is expected to close on October 1, 2025. The securities are being offered through a shelf registration statement previously filed with and declared effective by the SEC.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a proposed underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.

The securities will be offered through a "shelf" registration statement on Form S-3 that was previously filed and declared effective by the SEC on July 14, 2023. The final terms, size, and completion of the offering will depend on market conditions.

Artelo Biosciences (Nasdaq: ARTL) presented positive interim Phase 2 CAReS data for ART27.13 at the 2025 Cancer Cachexia Society Conference. The drug, targeting cancer anorexia-cachexia syndrome (CACS), demonstrated significant benefits in key metrics:

Patients receiving the highest dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while placebo patients lost ~5%. The treatment showed improvements in lean body mass and increased daily activity levels, confirmed through digital wearable data. The drug maintained a favorable safety profile with mostly mild to moderate adverse events and no serious drug-related incidents.

Professor Barry Laird from Oslo University Hospital presented the data, while the company engaged in partnering discussions to advance the program's commercial potential.

Artelo Biosciences (Nasdaq: ARTL) has published significant preclinical data for ART12.11, their proprietary CBD:TMP cocrystal, demonstrating superior efficacy in treating stress-induced depression and anxiety compared to CBD alone. The study, published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, revealed that ART12.11 achieved higher plasma concentrations and enhanced activation of endocannabinoid and serotonergic systems in key brain regions.

The research, conducted with Western Ontario University, showed ART12.11 reversed stress-induced behavioral deficits more effectively than CBD alone, TMP alone, or their non-crystalline mixture. Importantly, the MHRA has agreed to allow Artelo to leverage existing CBD and TMP data for their clinical trial application, potentially accelerating the pathway to human trials planned for next year.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $3.0 million in gross proceeds. The offering consisted of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase 40,894 shares at $4.399 per warrant.

The company granted underwriters a 45-day option to purchase up to an additional 102,272 shares to cover over-allotments. R. F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's shelf registration statement.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $3.0 million public offering. The offering consists of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at $4.399 per warrant.

The company has granted underwriters a 45-day option to purchase up to an additional 102,272 shares. R.F. Lafferty & Co. is serving as the sole book-running manager. The offering, expected to close on September 5, 2025, is being made through a shelf registration statement previously filed with the SEC.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the commencement of an underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.

The securities will be offered through a "shelf" registration statement previously filed with the SEC (File No. 333-273153) and declared effective on July 14, 2023. The company focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions through lipid-signaling pathway modulation.